[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577173":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":26,"locations":32,"responsibleParty":51,"collaborators":56,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sarcopenia",null,"Patients were diagnosed with sarcopenia on the basis of CT-quantified skeletal muscle mass index (SMI) during preoperative TIPS and postoperative follow-up. The European Association for the Study of the Liver clinical practice guidelines were used to determine the threshold value for sarcopenia, and SMI was calculated from the ratio of L3 cross-sectional area to height on CT images; those with \\\u003C50 cm²\u002Fm² in men and \\\u003C39 cm²\u002Fm² in women were diagnosed with sarcopenia. Patients with preoperative sarcopenia and 1-year postoperative sarcopenia who were still diagnosed with sarcopenia were in the sarcopenia group.",[13],"Procedure: Transjugular Intrahepatic Portosystemic Shunt",{"label":15,"type":10,"description":16,"interventionNames":17},"Non-sarcopenia","Patients were diagnosed with sarcopenia on the basis of CT-quantified skeletal muscle mass index (SMI) during preoperative TIPS and postoperative follow-up. The European Association for the Study of the Liver clinical practice guidelines were used to determine the threshold value for sarcopenia, and SMI was calculated from the ratio of L3 cross-sectional area to height on CT images; those with \\\u003C50 cm²\u002Fm² in men and \\\u003C39 cm²\u002Fm² in women were diagnosed with sarcopenia. Patients with sarcopenia before TIPS and without sarcopenia 1 year after TIPS were considered the non-sarcopenia group.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Transjugular Intrahepatic Portosystemic Shunt","All patients were treated with Transjugular Intrahepatic Portosystemic Shunt (TIPS).",[15,9],[25],"TIPS",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Jiacheng Liu Dr.","CONTACT","18627162379","1946046224@qq.com",[33],{"facility":5,"status":34,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Wuhan","430022","Taiwan","TW",{"type":40,"coordinates":41},"Point",[42,43],121.8128,24.71789,{"lat":43,"lon":42},[46,50],{"name":47,"role":29,"phone":48,"phoneExt":10,"email":49},"Yaowei Bai","+8618627162379","baiyaowei918@163.com",{"name":10,"role":29,"phone":10,"phoneExt":10,"email":49},{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":55,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jiacheng Liu","Clinical Professor","Huazhong University of Science and Technology",[57,59],{"name":58,"class":6},"The First Affiliated Hospital of Zhengzhou University",{"name":60,"class":6},"The First Affiliated Hospital of Henan University of Science and Technology","100577173","mechanism-of-tips-to-improve-sarcopenia-100577173",false,"NCT06794853","Mechanism of TIPS to Improve Sarcopenia","Mechanism of Transjugular Intrahepatic Portosystemic Shunt to Improve Sarcopenia by Down-regulation of FGF21","Inclusion Criteria:\n\n1. Diagnosed with liver cirrhosis and needing TIPS surgical treatment;\n2. Aged between 18-80 years old;\n3. Able to understand and sign the informed consent form and willing to cooperate in completing the examinations and follow-up visits.\n\nExclusion Criteria:\n\n1. Combination of serious cardiovascular and cerebrovascular diseases (such as acute myocardial infarction, severe heart failure, etc.);\n2. Suffering from malignant tumors and in the active stage;\n3. Recent (within 3 months) history of major surgeries or traumas;\n4. The presence of mental illness or cognitive disorders, which are unable to cooperate with the study;\n5. Undergoing other special treatments that may affect the results of the study (such as certain specific immune-suppressing agents, hormones, etc.)","ALL","18 Years","80 Years",{"count":72,"type":73},132,"ESTIMATED","OBSERVATIONAL","Sarcopenia is particularly common in patients with chronic liver disease, especially in patients with decompensated cirrhosis, where the prevalence can be more than 50%. Sarcopenia is an important risk factor for a significant increase in mortality in cirrhotic patients, and is closely associated with a high incidence of complications such as hepatic encephalopathy, ascites, and infections . Recent studies have found that TIPS not only significantly improves clinical symptoms caused by portal hypertension, but may also have a positive effect on skeletal muscle mass and function in patients. Although the effect of TIPS in improving sarcopenia has been preliminarily confirmed, its mechanism is not yet fully understood. Therefore, there is an urgent need to explore the mechanism of action of TIPS to improve sarcopenia and provide guidance for clinical treatment options.",[9,77,78],"Mechanism","Cirrhosis",[80,81,82],"sarcopenia","cirrhosis","FGF21","2026-02-07",{"date":85,"type":86},"2026-02-11","ACTUAL",{"date":88,"type":86},"2025-06-01",{"date":90,"type":73},"2027-12",{"name":5,"class":6},1]